gutflix
GI learning, personalised

Summary

LONG-TERM, REAL-WORLD TREATMENT PERSISTENCE AND MUCOSAL HEALING RATES WITH VEDOLIZUMAB IN PATIENTS WITH CROHN'S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Alessandro Armuzzi

UEG Week Copenhagen 2023 | Poster

IBD

October 17, 2023

A meta-analysis of 78 real-world studies including 30,158 adults with Crohn's disease found vedolizumab treatment persistence rates of 62.8% at 12 months and 54.9% at 24 months, with mucosal healing achieved in 38.4% at 12 months.

KEY POINTS

- Treatment persistence at 12 months was 81.0% in biologic-naïve patients versus 60.4% in biologic-experienced patients; at 24 months, persistence was 70.4% versus 41.9%, respectively.
- Mucosal healing at 12 months was achieved in 48.6% of biologic-naïve patients compared to 29.6% of biologic-experienced patients.
- The systematic literature review analyzed data from May 2014 to July 2022 using the DerSimonian-Laird random-effects model, with baseline patient characteristics including mean age 39.3 years and mean disease duration 12.5 years.
- Authors concluded that higher rates of treatment persistence and mucosal healing in biologic-naïve patients support early use of vedolizumab as a first-choice therapy.
- Clinicians managing moderate-to-severe Crohn's disease and considering long-term biologic therapy options would benefit from this real-world effectiveness evidence.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/5b22b928-743c-11ee-8c4c-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.